A 77-year-old male with a history of SAVR in 2011 (Magna Ease 23) and moderate chronic kidney disease, with preservedLV function, presented with symptomatic severe aortic regurgitation and stenosis, associated with severe MR.

A Sapien 3 Ultra Resilia 23 valve was implanted under local anesthesia, with hemodynamic...

A 53-year-old male with a history of advanced malignancy (lung adenoma) and mid LAD PCI last year, along with multiple risk factors (hypertension, dyslipidemia, diabetes, and smoking), presented with angina and a positive stress test and CT. The angiography and CT showed significant left main stenosis...

An 82-year-old male with a history of STEMI in 2013, stroke in 2018, cancer, and permanent AF, presented with acute heart failure with predominant right-side failure. Severe tricuspid regurgitation was identified.
The operators implanted an Evoque valve percutaneously under TEE guidance and general anaesthesia via the venous...

Join us for a LIVE case followed by a recorded case highlighting advanced treatments for severe secondary mitral regurgitation:

• A 75-year-old man with permanent AF, a history of CABG, and symptomatic severe secondary MR (atrial and ischemic causes) with low LV function (45%) underwent mitral repair with...

An 84-year-old woman with diabetes mellitus, frailty (5/6), preserved LV function, and aortic stenosis previously treated with CoreValve 26 mm in 2016, presented with symptomatic degenerative stenosis of the valve.
A Sapien 3 (23 mm) was implanted without predilatation but with post-dilatation under general anaesthesia, using cerebral...

The EuroIntervention Journal is pleased to announce its 2021 Impact Factor: 7.728 (2021 Journal Citation Reports® Science Edition (Clarivate Analytics, 2022)

With this result, we confirm last year's progression and we are proud to be listed 2nd amongst interventional cardiology journals. 

At TCT Connect 2020, Rodrigo Estevez-Loureiro presented the results of the IREMMI trial. Nicole Karam provides a summary of the key messages.

Alex Sticchi provides his take on the results of the RIVER trial, which were presented by Pedro Gabriel Barros E Silva during the ESC 2023 congress in Amsterdam.

Rivaroxaban versus Warfarin in Patients with Bioprosthetic Valves According to Valvular Heart Disease Etiology, and Thrombotic and Bleeding Risks: Insights from...

While Chiara De Biase interviews Helene Eltchaninoff about the RHEIA trial results, which she presented at the ESC Congress 2024 in London, Panos Xaplanteris shares his perspective on the trial, offering all the essential information and key takeaways you need for your practice!

Vijay Kunadian provides summaries of study designs and findings in Interventional Cardiology released at the 2021 virtual edition of the American Heart Association Congress. View an infographic of the AVATAR late-breaking trial by Ali Nazmi Calik.

Alex Sticchi provides his take on the TRIGISTRY study presented by Julien Dreyfus at the ESC Congress 2024 in London.

Simultaneous publication in European Heart Journal, ehae578

REDUCE-AMI is a multicentre, registry-based, prospective open-label parallel-group randomised clinical trial evaluating the benefit of beta-blocker treatment in patients with acute MI and an ejection fraction >50% treated with a contemporary reperfusion strategy.

Nicola Ryan and Ali Nazmi Calik provide their take on the results which were presented...

Ali Nazmi Calik provides his take on the EVOLVED trial presented by Marc Dweck at TCT 2024 in Washington.

At TCT Connect 2020, Late-Breaking Trial Session II, the primary results of the Safety and Efficacy Comparison of Two TAVI Systems in a Prospective Randomized Evaluation (SCOPE) 2 trial were presented and simultaneously published in Circulation. Daniele Giacoppo provides a summary of the trial.

Mirvat Alasnag provides her take on the TEER Shock study which was presented at TCT 2022 by Mohamad A. Alkhouli.